The four peptide families: a practical classification for patients

Dozens of names, four basic buckets. Once you know the buckets, the rest of the field stops feeling like alphabet soup.

TL;DR

• Most patient-facing peptides fall into four families: growth-hormone, repair-and-immune, metabolic, and brain-and-sexual signaling.
• The family tells you what the peptide is studied for, how it is monitored, and which side-effect profile to expect.
• The map below is for orientation. It is not a shopping list — every peptide requires a clinician evaluation.

What it is

A peptide is a short chain of amino acids (the building blocks of proteins). The body uses peptides as signals. Where a small molecule drug often acts like a blunt instrument, a peptide acts more like a precise text message to one specific receptor.

There are thousands of peptides in scientific literature. The ones used in clinical practice today cluster into four families. The map is not perfect — some peptides belong to two families — but it is the practical view a patient needs.

How it works

Think of it like the apps on a phone. The phone itself is the body. Each peptide family is a specific app — messaging, fitness, banking, calendar — built to talk to one system. Within an app, individual peptides are the contacts. You do not need to memorize every contact. You do need to know which app you are opening.

Family 1 — Growth-hormone signaling. Includes sermorelin, CJC-1295, ipamorelin, tesamorelin. These push the body's own pituitary to release growth hormone. Studied for body composition, sleep, and recovery.

Family 2 — Repair and immune. Includes BPC-157, TB-500, thymosin alpha-1, GHK-Cu. These influence tissue healing, immune balance, and inflammation. Most have stronger animal data than human data.

Family 3 — Metabolic. Includes GLP-1 agonists (semaglutide, tirzepatide, retatrutide). These work on the hunger, glucose, and fat-storage systems. Several are FDA-approved branded drugs; compounded versions are not FDA-approved.

Family 4 — Brain and sexual signaling. Includes PT-141 (bremelanotide), oxytocin, selank, semax. These act on central nervous system receptors that affect desire, mood, and arousal.

Who asks about it

People come to this question after seeing a podcast, a clinic menu, or a TikTok ad list ten peptides in one breath. They want a way to slow it down and ask the right next question. The family lens does that — it turns a wall of names into four short conversations.

What the research says

Each family has a different evidence base. Metabolic peptides have the largest randomized-trial pool. Growth-hormone peptides have decades of mechanism work and smaller efficacy trials. Repair-and-immune peptides have rich animal data and limited but growing human data. Brain and sexual signaling peptides have a mix — PT-141 is FDA-approved for hypoactive sexual desire disorder in premenopausal women; oxytocin has a long medical history; others are exploratory.

What to know before considering it

Family membership does not equal safety. Each peptide has its own dose, route, monitoring, and contraindications. Anyone prescribing or supplying a peptide without a clinician evaluation is skipping the part of the work where someone matches the right peptide to the right person.

The Halftime POV

Patients lose the thread because the field is presented as a list. A list is not an education. The four-family map is how a thoughtful clinician thinks about peptides — and we believe patients deserve the same lens.

Related reading:

• Peptide 101 FAQs
• The classic peptide stack: why CJC-1295 and ipamorelin work better together
• Tirzepatide vs semaglutide: dual vs single agonist comparison

---

FAQ

Q: How many types of peptides are there? A: Hundreds exist in research, but for patient-facing therapy the practical groups are four: growth-hormone family, repair and immune, metabolic and weight, and brain and sexual signaling.

Q: Are all peptides the same kind of drug? A: No. Peptides differ in route, target, and regulatory status. Some are FDA-approved finished drugs. Others are only available through state-licensed 503A compounding pharmacies. Many are not available through legitimate channels at all.

Q: Why does the family matter for a patient? A: It changes what the peptide is studied for, what side effects to expect, and how a clinician monitors progress.

Q: Is one family safer than another? A: Safety depends on the specific compound, dose, and patient — not the family. The honest path is a clinician evaluation, not a category.

---

Disclaimer

This article is educational and is not medical advice. Compounded medications are not FDA-approved. Clinical outcomes depend on individual factors and require physician evaluation. Results vary. Halftime Health is launching soon — join the waitlist to get updates.

Get updates

Halftime Health is launching soon. We'll share what we learn along the way — the research, the regulations, the real-world trade-offs. Join the waitlist and we'll email you when we're live.

---

Sources

• FDA, "Peptide and protein drugs"
• Lau JL, Dunn MK, "Therapeutic peptides: historical perspectives, current development trends, and future directions," Bioorg Med Chem (2018)

---

This article discusses compounds that are currently under FDA Category 2 review (see our FDA categorization explainer). These compounds are not currently part of Halftime Health's published protocol catalog. This article is provided for educational purposes only and does not constitute medical advice or an offer to sell.